Literature DB >> 32294340

Immune Thrombocytopenic Purpura in a Patient with Covid-19.

Abrar-Ahmad Zulfiqar1, Noël Lorenzo-Villalba1, Patrick Hassler2, Emmanuel Andrès3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32294340      PMCID: PMC7179995          DOI: 10.1056/NEJMc2010472

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
To rapidly communicate information on the global clinical effort against Covid-19, the A 65-year-old woman with hypertension, autoimmune hypothyroidism, and known Covid-19 exposure presented to the emergency department with a 4-day history of fatigue, fever, dry cough, and abdominal discomfort. She was afebrile and had a respiratory rate of 28 breaths per minute and an oxygen saturation of 89% while she was breathing ambient air; breath sounds were diminished bilaterally with bibasilar rales. The abdominal examination was normal. Laboratory tests showed a normal white-cell count, hemoglobin level (14.2 g per deciliter), and platelet count (183,000 per cubic millimeter). The C-reactive protein level was elevated at 55 mg per liter, and liver-function tests showed cholestasis. An oropharyngeal swab for Covid-19 testing was positive. Chest computed tomography (CT) showed ground-glass opacities in the lower zones. The patient was admitted and began to receive treatment with intravenous amoxicillin–clavulanic acid, low-molecular-weight heparin, and oxygen. On day 4, lower-extremity purpura (Figure 1) appeared and epistaxis occurred. Isolated thrombocytopenia (platelet count, 66,000 per cubic millimeter) was noted; these findings prompted discontinuation of heparin and antibiotics. On day 5, the platelet count was 16,000 per cubic millimeter, and on day 7, it was 8000 per cubic millimeter.
Figure 1

Purpuric Lesions on the Patient’s Lower Extremity.

The prothrombin and activated partial thromboplastin times were normal; the fibrinogen level was 5 g per liter (normal range, 2 to 4). A peripheral-blood smear showed less than 1% schistocytes. The level of thyroid peroxidase antibodies was 245 U per milliliter (normal value, <35); antiplatelet factor 4, antiplatelet antibodies, and antinuclear antibodies were not detected. Intravenous immune globulin was administered at a rate of 1 g per kilogram of body weight. After 48 hours, the platelet count decreased to 1000 per cubic millimeter and the purpuric lesions progressed; this prompted a second infusion of immune globulin at a dose of 1 g per kilogram.[1,2] Bone marrow aspiration showed normal cellularity with an increase in pleomorphic megakaryocytes. Erythroblast and granulocyte cell lines were normal, without evidence of hemophagocytosis. On day 9, a right frontal headache developed in the patient, without fever, vomiting, or focal neurologic deficit. CT of the head showed a subarachnoid microhemorrhage in the right frontal lobe. The platelet count was 2000 per cubic millimeter, and a platelet transfusion was administered with 100 mg of prednisolone; eltrombopag (75 mg per day) was initiated.[1,2] On day 10, the headache had resolved, there were no new neurologic findings, and the platelet count had increased to 10,000 per cubic millimeter. All the other laboratory tests had normalized except for the fibrinogen level, which remained elevated (3.5 g per liter). On day 13, the platelet count was 139,000 per cubic millimeter, and the purpura had disappeared. The temporal sequence in this case suggests,[3] but does not prove, that Covid-19 was a causal factor in immune thrombocytopenia in this patient. Fortunately, she had a response to treatment, albeit in a delayed fashion. Although the cerebral bleeding did not have major sequelae, this case illustrates the need to be vigilant for complications associated with Covid-19.
  126 in total

1.  Rogue antibodies could be driving severe COVID-19.

Authors:  Roxanne Khamsi
Journal:  Nature       Date:  2021-02       Impact factor: 49.962

2.  Overview of the Haematological Effects of COVID-19 Infection.

Authors:  T M Wiggill; E S Mayne; J L Vaughan; S Louw
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia.

Authors:  Pratik A Patel; Shanmuganathan Chandrakasan; Geoffrey E Mickells; Inci Yildirim; Carol M Kao; Carolyn M Bennett
Journal:  Pediatrics       Date:  2020-05-04       Impact factor: 7.124

Review 4.  Commonalities Between COVID-19 and Radiation Injury.

Authors:  Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo
Journal:  Radiat Res       Date:  2021-01-01       Impact factor: 2.841

5.  COVID-19 complicated by Hashimoto's thyroiditis.

Authors:  Louis Y Tee; Sumitro Harjanto; Barbara H Rosario
Journal:  Singapore Med J       Date:  2020-07-16       Impact factor: 1.858

6.  Non-Aneurysmal Subarachnoid Hemorrhage in COVID-19: A Case Report and Review of Literature.

Authors:  Ritwik Ghosh; Dipayan Roy; Adrija Ray; Amrita Mandal; Shambaditya Das; Shyamal Kanti Pal; Julián Benito-León
Journal:  Med Res Arch       Date:  2022-01-30

7.  Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication.

Authors:  Dina Sameh Soliman; Afaf Al Battah; Dekra Al Faridi; Feryal Ibrahim
Journal:  J Med Cases       Date:  2022-01-17

Review 8.  COVID-19-induced immune thrombocytopenic purpura; Immunopathogenesis and clinical implications.

Authors:  Mohammad Bahadoram; Ali Saeedi-Boroujeni; Mohammad-Reza Mahmoudian-Sani; Helai Hussaini; Shakiba Hassanzadeh
Journal:  Infez Med       Date:  2022-03-01

9.  Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information.

Authors:  Beatriz Burger; Hosana Gomes Rodrigues
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Coronavirus Disease 2019 and Cold Agglutinin Syndrome: An Interesting Case.

Authors:  Ruby Gupta; Sukhmani Singh; Nwabundo Anusim; Sachin Gupta; Sorab Gupta; Marianne Huben; George Howard; Ishmael Jaiyesimi
Journal:  Eur J Case Rep Intern Med       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.